Sullivan Mark 4

What Happened Mark Sullivan, Chief Legal Officer of Definium Therapeutics, was granted 125,000 restricted stock units (RSUs) on Feb 3, 2026. The award was reported on a Form 4 filed Feb 5, 2026. The reported acquisition price is $0.00, so there was no cash consideration paid for the RSUs.

Key Details

• Transaction date: 2026-02-03; Form 4 filed: 2026-02-05 (timely filing within the standard 2-business-day window).
• Grant: 125,000 RSUs; reported price: $0.00; reported value: $0.
• Shares owned after transaction: not specified in this filing.
• Footnote: RSUs represent a contingent right to receive one common share each. Vesting occurs in 16 equal quarterly installments beginning June 1, 2026, subject to continuous service. (Footnote F1)
• Transaction code: A = Award/Grant.

Context This grant is a compensation award (RSUs) rather than an open-market purchase or sale. Such awards are common for executive compensation and do not by themselves indicate a buy or sell signal. The RSUs are subject to time-based vesting (quarterly over four years), so actual share delivery depends on continued service and future vesting dates.